Premium
T cell replete–haploidentical second hematopoietic stem cell transplantation for primary graft failure in pediatric patients with hematologic malignancies
Author(s) -
Mochizuki Kazuhiro,
Sano Hideki,
Akaihata Mitsuko,
Kobayashi Shogo,
Waragai Tomoko,
Ohara Yoshihiro,
Takahashi Nobuhisa,
Ito Masaki,
Ikeda Kazuhiko,
Ohto Hitoshi,
Kikuta Atsushi
Publication year - 2017
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13043
Subject(s) - medicine , fludarabine , hematopoietic stem cell transplantation , transplantation , surgery , chemotherapy , cyclophosphamide
GF is one of the fatal complications of allogeneic HSCT . To rescue patients with primary GF, a second HSCT should be conducted as soon as possible, but the optimal donor source and technique have yet to be established. In this study, we retrospectively analyzed six children with hematologic malignancies who received TCR ‐haploidentical second HSCT for primary GF. The median interval between the prior HSCT and the second HSCT was 37.5 days. All patients received fludarabine and ATG containing reduced‐intensity re‐conditioning before the second HSCT . All patients, except one who died early, achieved both neutrophil and Plt engraftment at a median time of 15 and 33 days, respectively. Chimerism analysis showed that all engrafted patients achieved complete donor chimerism within 3 weeks. Four patients developed acute GVHD , and three patients developed chronic GVHD . TRM occurred in two patients. Median follow‐up of the four survivors was 6.8 years, and all remained in sustained remission until the last follow‐up. These results suggested that a TCR ‐haploidentical second HSCT for pediatric patients is feasible, and this approach may provide a potent option for children with primary GF.